7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
Published 2 months ago • 193 plays • Length 4:44Download video MP4
Download video MP3
Similar videos
-
2:43
four-year follow-up from a phase ii study of obinutuzumab, ibrutinib, and venetoclax in cll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
2:05
7-year follow-up of resonate-2 trial for cll/sll
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
12:05
venetoclax combinations, safety and efficacy
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
7:29
venetoclax obinutuzumab: impact on cll management
-
2:27
update on fixed-duration cohort of captivate trial for cll/sll
-
1:56
the future of fixed-duration therapy in cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
4:08
phase ib trial of ianalumab plus ibrutinib for cll
-
2:09
phase ii trial of venetoclax monotherapy for relapsed/refractory cll with 17p deletion
-
10:24
fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:57
the cll12 trial of ibrutinib in early stage cll
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations